Theranostics for Meningioma on the Rise: New EANM/EANO/RANO/SNMMI Guidelines Pave the Way to Improved Patient Outcomes Using Radiolabeled Somatostatin Receptor Ligands

J Nucl Med. 2025 Jan 3;66(1):24-25. doi: 10.2967/jnumed.124.268314.

Nathalie L Albert^{1

2

3}, Matthias Preusser⁴, Norbert Galldiks^{5

6

7}, Jana Ivanidze⁸

¹ Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany; nathalie.albert@med.uni-muenchen.de.
² German Cancer Consortium, Partner Site Munich, Munich, Germany.
³ Bavarian Cancer Research Center, Partner Site Munich, Munich, Germany.
⁴ Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
⁵ Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
⁶ Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany.
⁷ Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Germany; and.
⁸ Department of Radiology, Weill Cornell Medicine, New York, New York.

No abstract available

Publication types